Equillium, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
EQ Nasdaq 2836 www.equilliumbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Equillium, Inc.

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates - Nov 13th, 2024 9:01 pm
Equillium to Present at the Stifel Healthcare Conference - Nov 13th, 2024 1:00 pm
Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer - Nov 12th, 2024 1:00 pm
Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth - Nov 6th, 2024 3:00 pm
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates - Oct 31st, 2024 12:25 pm
Equillium Maintains Rights to Itolizumab Following Ono Partnership - Oct 31st, 2024 11:00 am
Alto Ingredients And 2 Other US Penny Stocks To Watch Closely - Oct 22nd, 2024 5:31 pm
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer - Oct 7th, 2024 12:00 pm
Equillium collaborates with Vivtex for oral formulation of autoimmune therapy - Sep 17th, 2024 3:54 pm
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit - Sep 10th, 2024 12:00 pm
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sep 4th, 2024 12:00 pm
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference - Aug 28th, 2024 12:00 pm
Equillium Second Quarter 2024 Earnings: Beats Expectations - Aug 11th, 2024 12:42 pm
Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates - Aug 8th, 2024 9:35 pm
Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights - Aug 8th, 2024 8:01 pm
Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease - Aug 6th, 2024 12:00 pm
Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance - Jul 18th, 2024 5:57 pm
Equillium to Participate in Upcoming Investor Conferences - Jul 2nd, 2024 12:00 pm
Equillium to be included in the Russell Microcap® Index - Jun 12th, 2024 12:00 pm
Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata - Jun 4th, 2024 12:00 pm